Gufic Biosciences Q4 FY26 Results

Revenue ₹252 Cr | PAT ₹20.5 Cr

Reader Takeaway: Indore plant breakeven is a positive; US FDA entry remains a key risk.

What just happened

Gufic Biosciences announced its Q4 FY26 financial results, showcasing significant year-on-year growth. Revenue for the quarter surged by 22.9% to ₹252 crore, compared to ₹205 crore in Q4 FY25. Profit After Tax (PAT) more than doubled, reaching ₹20.5 crore in Q4 FY26 from ₹8 crore in the same period last year. For the full fiscal year FY26, revenue stood at ₹940.50 crore, an increase from ₹820 crore in FY25, while PAT was ₹63.2 crore, down from ₹69.9 crore in FY25.

Why this matters

The strong top-line growth and significant PAT improvement in Q4 FY26 indicate a positive operational turnaround. The Indore manufacturing facility achieving EBITDA breakeven and 30% capacity utilization by FY26 is a major milestone, validating the company's largest capital expenditure. The strategic shift in the critical care division and the move towards an IP-focused international model are aimed at long-term financial health and sustainable revenue streams.

The backstory

Gufic Biosciences has been focusing on ramping up its Indore manufacturing facility and restructuring its business operations. The critical care division underwent a working capital reset, moving from direct hospital billing to a stockist-driven model, which impacted revenue by approximately ₹22 crore. The company is also transitioning its international business to an IP-led model, holding its own marketing authorizations.

What changes now

The company has guided for a 15% revenue growth in FY27. The Indore plant's margins are expected to reach 31%-32% once fully ramped, while Navsari margins are projected to stay around 18%-18.5%. The investment in Saraswat Bank for strategic banking relationships and favourable borrowing rates is also a notable operational change.

Risks to watch

The company's gross debt remains around ₹400 crore, which could limit immediate deleveraging options. A significant watch point is the complex and time-consuming US FDA entry process, which carries execution risk. Rising costs are also impacting 'other expenses' due to international dossier filings.

Peer comparison

(No specific peer comparison data was provided in the filing.)

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹252 Cr (up 22.9% YoY)
• Q4 FY26 PAT: ₹20.5 Cr (more than doubled YoY)
• FY26 Revenue: ₹940.50 Cr
• Indore Facility Utilization: 30% by end of FY26
• Gross Debt: ₹400 Cr

What to track next

Investors will be closely watching the execution of the US FDA inspection timeline, the performance of the new aesthetic portfolio, and the company's ability to achieve its 15% revenue growth guidance and margin targets for FY27. The successful implementation of the IP-focused international model will also be crucial for long-term earnings quality.